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The misuse of benzodiazepines 
among high-risk opioid users  
in Europe
I  Introduction
Benzodiazepines have a range of clinical uses and are among 
the most commonly prescribed medicines globally. They are 
useful in the short-term treatment of anxiety and insomnia, and 
in managing alcohol withdrawal (Medicines and Healthcare 
Products Regulatory Agency, 2015). Like all medicines, 
benzodiazepines can produce side effects. They may also be 
misused, which we define as use without a prescription from 
a medical practitioner or, if prescribed, when they are used 
outside accepted medical practice or guidelines. 
While the misuse of benzodiazepines has been identified as a 
concern for large groups in the general population, for example, 
among elderly people and women, this analysis focuses 
specifically on misuse among high-risk opioid users (1), a group 
of people among whom these medicines have been linked with 
severe treatment challenges and implicated in considerable 
numbers of drug-related deaths.
It is important to stress that much benzodiazepine prescribing 
to high-risk drug users is done with legitimate therapeutic 
aims in mind. Nevertheless, these medicines may be used in 
ways that produce unintended negative health consequences, 
especially when they are used for longer than two to three 
weeks, form part of polydrug use patterns — typically in 
combination with illicit drugs or alcohol — and are used in 
ways that do not accord with prescribing guidelines.
(1) A definition of high-risk opioid use is available on the EMCDDA website
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As is described below, the misuse of benzodiazepines 
contributes to increased morbidity and mortality among 
high-risk opioid users. It increases the risk of opioid overdose 
and is associated with a higher risk of acquiring HIV infection, 
experiencing anxiety and depression, and having poorer 
treatment outcomes and poorer social functioning (Darke et 
al., 1995; Ford and Law, 2014; Lader, 2012).
I  Benzodiazepine misuse among high-risk opioid users  
High-risk opioid users typically misuse benzodiazepines to 
self-medicate or increase the effects of opioids (Vogel et al., 
2013); reasons that may overlap. They self-medicate to treat 
symptoms of psychiatric disorders, negative emotional states, 
opioid withdrawal symptoms, and the side effects of alcohol 
and cocaine use. Benzodiazepines, especially when injected, 
can prolong the intensity and duration of opioid effects. For 
this reason, patients in opioid substitution treatment (OST) 
may misuse benzodiazepines in order to increase the effects 
of their opioid medication (Jones et al., 2012). Such misuse 
may be prompted by withdrawal symptoms caused by under-
dosing of the substitution treatment (Chen et al., 2011). 
High-risk opioid users generally take benzodiazepines orally, 
by snorting or by intravenous injection. While a range of 
different benzodiazepines are misused in Europe, those most 
commonly detected in drug-related deaths are diazepam, 
clonazepam, alprazolam, oxazepam and flunitrazepam. This 
suggests that this group may prefer to use benzodiazepines 
with a more rapid onset of action (e.g. diazepam, alprazolam) 
than those with a slower onset (e.g. oxazolam, prazepam). 
The type of benzodiazepines used may be influenced by a 
range of factors, such as personal preferences, availability 
and price. Shifts from one type of benzodiazepine to another 
have been observed after changes in legal status or other 
regulatory measures. In France, for example, after restrictions 
were imposed on flunitrazepam prescriptions, misuse of 
the drug decreased while misuse of clonazepam increased 
(OFDT, 2005). In the United Kingdom, the withdrawal of 
temazepam capsules and stricter prescribing practices 
appears to have increased the use of diazepam (as well as 
‘Z-drugs’) (2) and prompted the use of ‘new’ benzodiazepines, 
such as phenazepam and etizolam, which were not originally 
controlled under drug legislation (Johnson et al., 2016).
Benzodiazepines are obtained from different sources, 
including diversion of prescriptions (through practices such 
as ‘doctor shopping’) (3), the illicit market and the internet. 
A growing number of new benzodiazepines have been 
identified for sale at street level and online. In many cases, 
these have not been authorised as medicines within the 
European Union (EU), for example, flubromazolam  
and flubromazepam.
I  The increasing number of new benzodiazepines
Over the last decade, the EU Early Warning System on new 
psychoactive substances (4) has detected an increasing 
number of new benzodiazepines that have appeared 
on Europe’s drug market (5) (Figure 1), with more than 
half having been detected since 2015. The first of these 
were phenazepam in 2007 and etizolam in 2011. Four of 
these drugs — etizolam, diclazepam, flubromazolam and 
phenazepam — account for over 80 % of all tablets containing 
new benzodiazepines that have been seized in Europe since 
2005 (6). Phenazepam, which is now a controlled drug, has 
(2) Zaleplon, zolpidem and zopiclone and related medicines (sometimes referred to 
as ‘Z-drugs’) are a group of non-benzodiazepine hypnotic drugs with pharmacology 
similar to benzodiazepines.
(3) ‘Doctor shopping’ refers to the practice of patients requesting care from multiple 
physicians, often simultaneously, without making efforts to coordinate care or 
informing the physicians of the other caregivers. This usually stems from a patient’s 
addiction to, or reliance on, certain prescription drugs or other medical treatment.
(4) http://www.emcdda.europa.eu/activities/action-on-new-drugs
(5) New psychoactive substances, including new benzodiazepines, are 
psychoactive substances that are not under international control. However, over 
time, some of these substances may be assessed as being particularly harmful 
and brought under control.
(6) Based on seizure data reported to the EU Early Warning System.
Figure 1. Timeline of the reporting of new benzodiazepines to the EMCDDA
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been linked to hospitalisations and deaths. It can cause 
psychomotor impairment, respiratory arrest, psychosis and 
delirium. It is sold on the internet and the illicit market as a 
powder, tablets and blotters. 
Some of the new benzodiazepines, such as phenazepam, have 
been approved and marketed for use in a few countries in the 
past, others may be found in the patent literature but have 
never been brought to market, and some are novel compounds. 
The majority have never undergone clinical trials or tests 
(Manchester et al., 2017). New benzodiazepines may provide 
an attractive alternative to prescribed benzodiazepines for 
misuse because they are readily available via the internet or are 
sold on the illicit market. Their pharmacology and toxicology is 
largely unknown and they may pose higher risks to users.
Another issue that has emerged is that new benzodiazepines 
have been found mixed with other new psychoactive 
substances, including synthetic cannabinoids (Couch and 
Madhavaram, 2012). Furthermore, counterfeit diazepam 
tablets have been seized in in Europe that contained a new 
potent synthetic opioid. These tablets pose a serious risk to 
users, who will not be aware that they are using a potent opioid. 
I  Extent of benzodiazepine misuse among high-risk opioid users
Benzodiazepine misuse among high-risk drug users, like other 
forms of high-risk drug use, cannot be measured by direct 
methods, such as surveys of the general population. Insights 
into the scale of the problem can, however, be gained from 
data collected from those entering specialised drug treatment 
in Europe. Treatment demand data (7) do not allow us to gauge 
the full scale of benzodiazepine misuse, but they give some 
important insights into the scope of the problem. These data 
show that the combined use of opioids and benzodiazepines 
is reported by a considerable number of those receiving 
treatment. Data from 23 countries (8) show that, among the 
42 700 treatment entrants in 2015 who reported opioids as 
their primary problem drug (9) (40 % of all  clients entering 
treatment), benzodiazepines were reported as a secondary
(7) European countries provide data according to the same protocol (Treatment 
demand indicator standard protocol 3.0) on the characteristics and patterns of drug 
use of people entering drug treatment for problems related to their drug use (www.
emcdda.europa.eu/publications/manuals/tdi-protocol-3.0).
(8) Data from 23 of 30 countries: Austria, Belgium, Croatia, Cyprus, Czech Republic, 
Denmark, Finland, France, Greece, Ireland, Italy, Luxembourg, Malta, Netherlands, 
Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Turkey, United 
Kingdom.
(9) The primary drug is defined as the drug that causes the client the most problems 
at the start of treatment. This is usually based on the request made by the clients 
and/or on the diagnosis made by a therapist, commonly using international 
standard instruments (e.g. ICD-10; DSM-IV; ASI) or clinical assessment. This item is 
of central importance and it should be collected for every client. Secondary drugs 
are those drugs used in addition to the primary drug, and are substances that cause 
problems for the client and/or change the nature of the problem as assessed by 
the client and the therapist (www.emcdda.europa.eu/publications/manuals/tdi-
protocol-3.0) 
 
problem drug (10) by 12 000 or 12 % of the opioid clients 
who reported a secondary problem drug (Figure 2). Higher 
levels, ranging from 30 % to 50 % of those entering treatment 
with opioids as their primary problem drug, were reported 
in some countries. However, these figures are probably 
under-estimates because problems with secondary drugs, 
including benzodiazepines, are often under-reported. Data 
on benzodiazepine misuse among high-risk opioid users in 
treatment indicate a relatively stable trend between 2006 and 
2013. 
Other studies have found prevalence rates of benzodiazepine 
misuse among clients in OST ranging from 45 % in France 
(Brisacier and Collin, 2014) to 70 % in Germany (Laqueille et 
al., 2009; Specka et al., 2011). The frequency of benzodiazepine 
misuse is reported to increase with the length of OST treatment 
(Fernández Sobrino et al., 2009). This factor has also been 
identified in treatment outcome studies (Comiskey, 2013; 
Stewart et al., 2002). High rates of benzodiazepine misuse 
have also been found among high-risk opioid users in prisons. 
One study in 38 Italian prisons found that 85 % of opioid users 
misused benzodiazepines (Nava, 2014). A study of French 
male prisoners found that 37 % were chronic benzodiazepine 
misusers and that many high-risk opioid users switched from 
illicit opioids to benzodiazepines when incarcerated, either to 
make their incarceration bearable or to cope with withdrawal 
symptoms (Expertise Collective, 2012). 
In addition to the 12 000 people entering treatment primarily 
for opioid-related problems, who also report benzodiazepines 
as a problem drug, benzodiazepines are reported as the 
primary problem drug by around 8 150, or 2 % (range: 0 to 
9 %), of all treatment entrants. Of the primary benzodiazepine 
clients who reported a secondary drug, 36 % cited opioids as a 
(10) A secondary drug should be recorded ‘only if it causes problems to the client 
according to the client’s request and to the professional’s assessment’ (TDI version 
3.0).
Figure 2. Frequency of reporting different substances as 
a secondary drug by clients entering drug treatment for 
primary opioid problems
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secondary problem drug. Benzodiazepines were reported 
as the primary problem drug by more than 5 % of treatment 
entrants in three countries: Belgium, Ireland and Finland.
I  Health harms associated with benzodiazepine misuse
Among both the general population and vulnerable groups, 
such as high-risk opioid users, the prolonged use and misuse 
of benzodiazepines can cause a range of harms to health. 
These include problems associated with rapid development 
of tolerance, dependence and withdrawal symptoms, which 
can, in people who have particular vulnerability, include 
increased anxiety, agitation, confusion, panic attacks and 
acute psychosis. Abrupt benzodiazepine withdrawal can 
cause uncontrollable and potentially fatal convulsions 
(Ashton, 1986; Jones et al., 2012). The cessation of regular 
benzodiazepine use requires medical support and this may 
include the use of other medications to manage withdrawal 
symptoms or provide substitution. The withdrawal process 
may need to occur in an inpatient setting. The prolonged use 
of benzodiazepines has been linked with long-term adverse 
effects such as over-sedation, depression and immune 
system problems. Europe’s ageing high-risk opioid users 
are at increased risk of side effects, which can be more 
pronounced in the elderly. In addition, polydrug use involving 
opioids and benzodiazepines can also expose users to other 
risk behaviours and drug-related harms, such as needle-
sharing, using high doses of drugs, intoxication-related 
accidents, and poor physical and psychological health (Lavie 
et al., 2009; Rooney et al., 1999; Vogel et al., 2013).
Opioid users who misuse benzodiazepines experience a 
high level of health problems and frequently use health 
services. For example, the Australian Treatment Outcome 
Study (ATOS) (Darke et al., 2003) found that heroin users 
who also misused benzodiazepines had more general 
practitioner (GP) and psychiatrist visits, were more likely 
to have required an ambulance, and had more dispensed 
prescriptions than heroin users who did not. A study in France 
of patients prescribed buprenorphine for opioid dependence 
found that the co-prescription of benzodiazepines had no 
impact on opioid treatment outcome but was associated with 
more emergency department visits and accidental injuries 
(Schuman-Olivier et al., 2013).
I  Overdose
The simultaneous use of opioids with benzodiazepines 
and other central nervous system depressants, such as 
alcohol, increases the risk of non-fatal and fatal overdose 
through respiratory depression (White and Irvine, 1999). 
The increased risk of overdose among opioid users is 
reflected in the high frequency with which benzodiazepines 
are identified post-mortem in drug-related deaths. For 
example, benzodiazepines were identified in 40 to 80 % of 
methadone-related deaths (France, United States, Australia) 
and in 50 to 80 % of heroin-related deaths (Germany, Ireland, 
United Kingdom) (Lintzeris et al., 2007). Data reported 
to the EMCDDA show further evidence of the presence 
of benzodiazepines in a large proportion of drug-related 
deaths, many of which are opioid-related, for example 
benzodiazepines were found in 88 % of cases in Finland 
(Ojanperä and Kriikku, 2014), 73 % in Scotland (National 
Records of Scotland, 2017) and 41 % in Portugal (11). In 
addition, benzodiazepines were thought to have played 
a role (were implicated) in 49 % of drug-related deaths in 
Scotland (National Records of Scotland, 2017), 48 % in 
France (Mallaret, 2014) and 35 % in Ireland (Lynn, 2014). It is 
important to note that in some deaths, benzodiazepines may 
have played a role in risk behaviours that led to the death, 
although they were not reported to be the cause of death or 
as a contributing factor.
In France, where buprenorphine is more often used 
than methadone for opioid substitution treatment, fatal 
poisonings involving combinations of benzodiazepines and 
buprenorphine have been reported (Reynaud et al., 1998); 
benzodiazepines were identified in 70 % of buprenorphine-
related deaths (Mallaret, 2014). While buprenorphine 
causes less respiratory depression than methadone, its 
ceiling effecton respiratory depression is removed when it is 
combined with benzodiazepines (Nielsen and Taylor, 2005). 
For all opioids, establishing the role of benzodiazepines in 
drug-related deaths is complicated by several factors. For 
(11) Data reported by the Portuguese national focal point to the EMCDDA in 2017 
(data for 2016: 11 out of 27 drug-related deaths).
Credit: iStock
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instance, a complex combination of drugs may be involved, 
individuals have different metabolisms and levels of 
tolerance to different drugs, and there is some subjectivity in 
toxicological assessments of their role in cause of death.
I  Challenges for the future
Benzodiazepines are well-established medicines for a range 
of short-term clinical uses but they also have adverse side 
effects. Their widespread availability increases the potential 
for the misuse of these drugs to pose a serious public 
health problem, particularly where they are taken by opioid 
users as part of polydrug use repertoires. The picture that 
emerges from research and epidemiological data presents 
a challenging situation. Benzodiazepines may have a role 
in managing mental health issues that opioid users often 
experience, but their misuse alongside other drugs can 
increase mental health problems, compromise treatment 
outcomes, and increase risky drug consumption practices, 
leading in some cases to more severe consequences, such as 
non-fatal and fatal overdoses. Benzodiazepine misuse among 
high-risk opioid users has often been viewed by both users 
and service providers as an issue of secondary importance, 
thereby neglecting the effects of polydrug use and its serious 
consequences. 
With continuing use of benzodiazepines for various medical 
purposes, prescribing and clinical practice guidelines have 
a critical role to play in mitigating the risks opioid users 
taking them face. However, few evidence-based guidelines 
addressing the management of benzodiazepine use among 
high-risk opioid users are currently available. Such guidelines 
need to be part of a comprehensive response to polydrug use 
among high-risk opioid drug users. This is a challenge that 
treatment systems must address given that this population is 
ageing in Europe and have an increased risk of serious health 
complications from their ongoing drug use.
The situation is complicated by the emergence on the illicit 
market in some countries of new benzodiazepines, such as 
phenazepam and etizolam, which may increasingly contribute 
to deaths among opioid users. For example, in Scotland in 
2016, such new benzodiazepines were responsible for most 
of the rise in drug-related deaths in which benzodiazepines 
were implicated or potentially contributed, and etizolam 
overtook diazepam as the benzodiazepine most frequently 
reported in drug-related deaths (National Records of 
Scotland, 2017). In illicit markets these substances are 
not only sold as benzodiazepines but may also appear 
as contaminants or be marketed in place of other new 
psychoactive substances or illicit drugs, potentially increasing 
the risks associated with them. In addition, in some EU 
countries, such as Ireland and the United Kingdom, concerns 
have recently been raised that the availability of extremely 
cheap illicit benzodiazepines, including new benzodiazepines, 
on the internet may be leading to increased use of these 
drugs by vulnerable teenagers, often in combination with 
alcohol. This pattern of use is reported to be linked to 
behavioural problems, as well as posing a risk of overdose. 
This highlights the need for monitoring systems and 
services to be alert to the potential risks associated with 
benzodiazepine use and how these may be changing. 
Video on misuse of benzodiazepines among high-risk opioid users, available on the 
EMCDDA website: www.emcdda.europa.eu/topics/pods/benzodiazepines
I  Interactive element: video
Insights from hospital emergency departments
The European Drug Emergencies Network Plus (Euro-DEN 
Plus) project has been collecting data on presentations to 
sentinel emergency departments across Europe with acute 
recreational drug toxicity since October 2013.
The Euro-DEN Plus project analysed 16 033 presentations 
(involving 24 538 drugs) with acute drug toxicity over the 
3-year period from January 2014 to December 2016, from 
21 sentinel centres in 14 European countries. There was a 
total of 3 742 presentations involving acute toxicity related 
to the self-reported use of heroin, of these 1 851 had used 
only heroin while 922 had used heroin together with at 
least one benzodiazepine. The most frequently reported 
benzodiazepines associated with heroin were clonazepam, 
‘unknown benzodiazepine’, diazepam and alprazolam. 
Over the same period, the Euro-DEN Plus project recorded 
2 767 benzodiazepine-related emergency department 
presentations (17.3 % of all Euro-DEN Plus presentations).  
The most commonly recorded benzodiazepine was 
clonazepam, followed by ‘unknown benzodiazepine’, 
diazepam and alprazolam. There were geographical 
differences, both in terms of the proportion of presentations 
involving benzodiazepines (more common in Estonia, 
Germany, France, Ireland and Norway; less common in Malta, 
Poland and the United Kingdom) and in the benzodiazepines 
involved (clonazepam most common in Norway, and 
bromazepam in France).
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I  Facts and figures 
Benzodiazepines were introduced into clinical medicine 
in the early 1960s. They rapidly replaced barbiturates as 
sedative-hypnotics because they were safer and less likely 
to cause fatal central nervous system depression (Longo 
and Johnson, 2000; EMCDDA drug profile). 
Benzodiazepines act as central nervous system depressants 
by enhancing the actions of the neurotransmitter GABA 
(gamma-aminobutyric acid). They have a calming effect on 
many functions of the brain and induce sedation and sleep 
(Lalive et al., 2011). 
They are used for treating psychiatric and neurological 
conditions, including insomnia, anxiety disorders, alcohol 
dependence and epilepsy. Some are used as pre-
anaesthetic and intraoperative medications (Medicines 
and Healthcare Products Regulatory Agency, 2015).
Benzodiazepines can be divided into different groups based 
on their chemical structure and pharmacokinetic properties 
but they all share a common mechanism of action and 
produce similar pharmacological effects (Baldwin et al., 
2013).
Benzodiazepines can be placed into one of three groups 
based on their pharmacokinetics. These are short-acting 
agents, with half-lives of less than 6 hours (e.g. oxazepam); 
intermediate-acting agents, with half-lives of 6 to 24 hours 
(e.g. alprazolam); and long-acting agents, with half-lives of 
over 24 hours (e.g. diazepam) (Medicines and Healthcare 
Products Regulatory Agency, 2015).
The benzodiazepines that are under international control at 
the time of writing and the schedule under which they are 
classified are shown in the table below.
Year of scheduling decision Schedule Substance name
1984 IV Alprazolam
Bromazepam
Camazepam
Chlordiazepoxide
Clobazam
Clonazepam
Clorazepate
Clotiazepam
Cloxazolam
Delorazepam
Diazepam
Estazolam
Ethyl loflazepate
Fludiazepam
Flurazepam
Halazepam
Haloxazolam
Ketazolam
Loprazolam
Lorazepam
Lormetazepam
Medazepam
Nimetazepam
Nitrazepam
Nordazepam
Oxazepam
Oxazolam
Pinazepam
Prazepam
Temazepam
Tetrazepam
Triazolam
1990 IV Midazolam
1995 III Flunitrazepam
IV Brotizolam
2016 IV Phenazepam
Source: UNODC (2017) p. 5.
International control of benzodiazepines under the United Nations Convention on Psychotropic Substances of 1971
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There are few evidence-based clinical guidelines to 
support practitioners in the use and management of 
benzodiazepines among high-risk opioid users. The 
EMCDDA’s Best practice portal (www.emcdda.europa.eu/
best-practice) contains seven sets of guidelines as part 
of general or specific guidelines for managing the use of 
opioids, benzodiazepines or both. 
 
The Substance Misuse Management Good Practice 
Guidance for the use and reduction of misuse of 
benzodiazepines and other hypnotics and anxiolytics 
in general practice in the United Kingdom (Ford and 
Law, 2014), has a section that focuses on addressing 
benzodiazepine use by people who use illicit drugs, 
particularly opioids. Similarly, a recent US Food and Drug 
Administration Drug Safety Communication (FDA, 2017) 
provides advice on medication management where there 
is combined use of prescribed opioids, including opioid 
substitution medications and benzodiazepines. 
 
Some evidence reviews are also relevant. Soyka 
(2017) considers the evidence for the management of 
benzodiazepine withdrawal, including among patients 
receiving opioid maintenance therapy. A Cochrane review 
(Darker et al., 2017) considers the evidence concerning 
the effectiveness of psychosocial interventions for 
benzodiazepine harmful use, abuse or dependence. 
 
A number of key messages for those addressing 
benzodiazepine use among opioid users emerge from these 
different sources: 
 
        Educate patients about the risks of combined opioid 
and benzodiazepine use, including overdose and death, 
both when used as prescribed and when obtained illicitly. 
Also include education about the risk of concomitant 
alcohol use. 
 
        Develop strategies to manage the use of prescribed 
or illicit benzodiazepines or other CNS depressants when 
starting opioid substitution treatment. Discuss with patients 
how they may control and reduce their benzodiazepine use 
(without the need for a benzodiazepine prescription). 
 
        Treat the opioid dependence first, stabilising and 
optimising opioid maintenance dose. 
 
        Re-assess patients’ benzodiazepine use once they are 
stable on their opioid prescription because benzodiazepine 
use may cease or reduce after their opioid maintenance 
treatment has been optimised. 
 
        If dependence on benzodiazepines is present, consider 
a short-term (6 weeks to 6 months), tapering prescription 
of benzodiazepines (if appropriate consider substitution 
with a benzodiazepine with longer duration of action before 
tapering). 
 
        If a patient is prescribed benzodiazepines or other CNS 
depressants for anxiety or insomnia, verify the diagnosis 
and consider other pharmacological options, along with 
behavioural interventions, for the treatment of these 
conditions. 
 
        Monitor for drug use and stop the benzodiazepine 
prescription if persistent use of illicit drugs, off-prescription 
use of benzodiazepines or alcohol dependence is present. 
Consider similar staged detoxification as with other patients 
dependent on benzodiazepines. 
 
        Coordinate care to ensure other prescribers are aware 
of the patient’s opioid maintenance treatment and the need 
to avoid prescription of benzodiazepines and other CNS 
depressants. 
 
Recommendations for practice  
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